<DOC>
	<DOCNO>NCT02381405</DOCNO>
	<brief_summary>This open label , randomize investigation proprietary blend amino acid , call Enterade® , effect irregularity ( diarrhea ) cause radiation therapy and/or chemotherapy include TKI* . Subjects randomize receive Enterade® continue standard care . Two patient enrol treatment arm patient control arm .</brief_summary>
	<brief_title>A Study Evaluating Proprietary Amino Acid Mixture ( Enterade® ) - Maintaining Bowel Regularity Patients With GI Toxicity From Any Combination Therapy Including Tyrosine Kinase Inhibitors ( TKI )</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<criteria>1 . Patients combination therapy include radiation therapy alone , chemotherapy alone , TKI alone , combination eligible . 2 . This include patient therapy include Xeloda ( capecitabine ) , Camptosar ( irinotecan ) 5FU ( fluorouracil ) cancer . 3 . Patients diagnose CID CTCAE toxicity grade 3 high 4 . Patients must least 18 year age . 5 . ECOG performance status 02 . 6 . Patients must diarrhea symptom , judge secondary systemic therapy , combine systemic therapy , and/or radiation , must require loperamide similar ( Imodium® ) symptom management . For purpose study , diarrhea define three loose liquid stool per day loose watery stool ( great volume stool ) occur frequently usual lasting three day . 1 . ECOG performance status 3 great . 2 . Pregnant and/or breastfeed woman 3 . Premenopausal subject well subject ovarian radiation concomitant treatment LHRH agonist/antagonist must negative pregnancy test agree use adequate method contraception recommend treat physician 4 . Postmenopausal status define either : 1. age ≥55 year one year amenorrhea , 2. age &lt; 55 year one year amenorrhea estradiol assay &lt; 20 pg/mL 3. bilateral oophorectomy 4 . CID CTCAE grade 1 2 ( require Loperamide similar )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>